References in periodicals archive ?
Care provided in these clinics included Pap test screening, colposcopic examinations, and treatment of identified cervical dysplasia with cervical cryotherapy, conization, and loop excision of the ectocervical portion (LEEP).
Cancer treatment company Inovio Pharmaceuticals Inc (NYSE Amex:INO) reported on Tuesday the receipt of the US Patent No 8,168,769 that covers its SynCon vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV) from the US Patent and Trademark Office.
In 1993 the family practice residency program at Via Christi Regional Medical Center in Witchita, Kansas, began the Cervical Dysplasia Clinic.
The large majority of cervical dysplasia in adolescents resolves on its own without treatment.
Although the presence of LSIL increases the risk of cervical dysplasia, only 1% of the survey respondents said they believed that the copper T 380 and levonorgestrel intrauterine systems worsen cervical dysplasia.
Preterm birth and cervical dysplasia share many risk factors, most of which are the progeny of low socioeconomic status.
But only 35% were aware of recent scientific evidence showing that most HPV infections clear without medical intervention, that anogenital warts do not increase the risk of cancer at the same site where the warts are located (38%), and that the HPV types associated with warts are not the same as the types associated with cervical dysplasia (47%).
Only 38% of respondents knew that anogenital warts do not increase the risk of cancer at the same sites where the warts are located, and only 47% knew that genital HPV types usually associated with external anogenital warts are not the same HPV types associated with cervical dysplasia and cancer.
Of the 66 reported cytology specimens, 18 showed cervical dysplasia or atypical squamous cells.
Screening for precursors of cervical cancer with colposcopic examination for women with abnormal Papanicolaou (Pap) smears identifies those with cervical dysplasia.
OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, completes recruitment of the first group of patients in its US cervical dysplasia (CIN) phase II study of ADXS11-001 as required for the planned DMSB (safety board) meeting scheduled to be held January 11, 2011.
The company will use this grant for three of its projects, including the Phase II clinical trial of VGX-3100, a therapeutic vaccine for cervical dysplasia and cancer as well as development projects for SYNCON universal flu and dengue vaccines.